Olema Pharmaceuticals, Inc. 8-K

What Happened
Olema Pharmaceuticals, Inc. announced on January 12, 2026 (8‑K filing) that its preliminary, unaudited cash, cash equivalents and marketable securities as of December 31, 2025 exceed $500 million. The company noted it has not completed its fiscal year‑end close and the amount is an estimate subject to change. Olema also made an investor presentation available on its website (furnished as Exhibit 99.1).

Key Details

• Preliminary cash, cash equivalents and marketable securities: greater than $500 million (as of December 31, 2025).
• Filing date: January 12, 2026; signed by Shane Kovacs, Chief Operating and Financial Officer.
• Status: preliminary and unaudited; independent registered public accounting firm has not audited, reviewed, or performed procedures on this estimate.
• Additional disclosure: investor presentation furnished as Exhibit 99.1; company said this estimate should not replace the audited Form 10‑K for FY‑end 2025.

Why It Matters
A cash balance above $500M is a material indicator of Olema’s financial condition and potential runway for operations, clinical programs or other corporate activities. However, investors should treat this as a preliminary estimate—subject to change upon completion of year‑end close and audit—and rely on the Company’s forthcoming Form 10‑K for audited, complete financial statements and fuller context. The 8‑K also includes standard forward‑looking statement disclaimers and notes the company has no obligation to update this preliminary estimate.